Pulmonary capillary wedge pressure (PCWP), BMI and stroke volume were independently associated with the presence of HFpEF, compared with healthy subjects exercising at the same workloads.

ACC 2019 In an echocardiography substudy of the COAPT trial, predictors of poor outcomes were studied in HF patients with severe secondary mitral regurgitation.

ACC 2019 An open-label extension study of the PIONEER-HF trail showed that in-hospital initiation of sacubitril/valsartan (S/V) improved clinical outcomes after ADHF among HFrEF patients, compared to in-hospital initiation of enalapril followed by S/V.

ACC 2019 Post-approval analyses of the CardioMEMS PAS trial showed that adapting therapy based on pulmonary artery pressure is effective in reducing hospitalizations for HF and safe in patients with NYHA class III HF.

ACC 2019 Dr. Adam DeVore discusses the results of an open-label extension study of PIONEER-HF. In this study, the effect of sacubitril/valsartan in acute HF was confirmed, showing greatest benefit when started early during hospitalisation.

ACC 2019 An analysis of DECLARE-TIMI 58 showed that dapagliflozin was associated with reduced hospitalization for HF and CV death across a range of EF. Benefit seems largest in HFrEF.

This observational study showed prognostic value of IL-1β for acutely decompensated HF (ADHF) in those with high sST2 (IL-1 receptor) levels, and a meaningful correlation between IL-1β and sST2.

In real-world setting, HFrEF patients who developed worsening HF had high comorbidity burden and poor outcomes, with low observed medication use and suboptimal dosing before and after chronic worsening HF events.

The contemporary CHAMP-HF registry of HFrEF patients revealed that <10% of patients eligible for ACEi/ARB/ARNI and BB therapy received target doses, also when SBP was >110 mmHg.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

The combination of sacubitril/valsartan reduced mitral regurgitation, measured by change in effective regurgitant orifice area, to a greater extent than valsartan alone in HF patients in the PRIME study.

A post-hoc analysis of the TOPCAT trial showed increased absolute risk for study drug discontinuation due to AEs with spironolactone in HFpEF patients with eGFR ≤60 mL/min/1.73m², compared to higher eGFR categories.